Cullinan Therapeutics, Inc.

NASDAQ:CGEM

Medical - Pharmaceuticals

Healthcare
$9.01 +4.29%

+$0.62 today

Market cap
$584.94M
Beta
0.01
P/E (TTM)
-4.0
EPS (TTM)
-$3.73
52W Low $5.68High $16.74

Volume 1.06M

Average 0.99M

CGEM Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Cullinan Therapeutics, Inc.NASDAQ: CGEM

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity falls 33.6% from a year ago

Total equity stood at $366.17M at the end of Q1 FY2026, down 33.6% from a year earlier and down 10.4% from the prior quarter. Over 3 fiscal years it compounded at -8.6% a year.

Context

  • Total equity amounted to 90.9% of total assets at the end of Q1 FY2026, down 4.3 pp from a year earlier.
  • Total equity increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps falling in the next quarterly balance sheet after a -33.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$366.17M-10.4% QoQ
Last fiscal yearDec 2025
$408.73M-30.8% YoY
Year agoMar 2025
$551.84M-33.6% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-33.6%——
1 year-30.8%——
3-year CAGR-8.6%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
408.73M USD
Year-over-year change
-30.8%
4-year CAGR
-1.0%

Total Equity vs competitors

How CGEM compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -33.6% is the 10th highest of 11, against a peer median of +17.5%.
  • Total equity amounts to 90.9% of total assets for CGEM, versus a peer median of 78.4%.
CGEM Competitors
Total Equity for CGEM and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
LEGNLegend Biotech CorporationSep 2026$1.27B USD+25.9%+10.4%75.7%
NRIXNurix Therapeutics, Inc.Aug 2026$968.31M USD+160.1%+21.1%81.0%
JANXJanux Therapeutics, Inc.Mar 2026$941.54M USD-7.0%+44.0%91.6%
XNCRXencor, Inc.Jun 2026$503.23M USD-18.9%-4.4%69.4%
IMTXImmatics N.V.Mar 2026€456.28M EUR-15.0%+31.4%83.9%
CGEMCullinan Therapeutics, Inc.Mar 2026$366.17M USD-33.6%-8.6%90.9%
AVBPArriVent BioPharma, Inc. Common StockMar 2026$323.98M USD+60.0%+20.8%92.8%
ALXOALX Oncology Holdings Inc.Mar 2026$151.35M USD+71.4%-53.8%84.9%
CGENCompugen Ltd.Mar 2026$95.35M USD+67.0%+9.8%65.4%
MGNXMacroGenics, Inc.Mar 2026$21.2M USD-73.2%-26.8%9.7%
ADCTADC Therapeutics S.A.Mar 2026-$216.38M USD+9.2%—74.2%
Peer median (excluding CGEM) —+17.5%+10.4%78.4%

Competitors are the stored peer set for CGEM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents59.77M156.15M98.43M83.01M88.33M
Short-term Investments230.69M311.14M368.63M315.97M289.56M
Net Receivables0003M0
Inventory00000
Other Current Assets07.18M13.12M12.69M8.86M
Total Current Assets296.56M474.47M480.19M414.67M386.76M
Property, Plant & Equipment (Net)77K5.3M3.53M2.35M3.05M
Goodwill00000
Intangible Assets00000
Long-term Investments140.4M80.88M0204.44M58.27M
Tax Assets00000
Other Non-current Assets147K459K459K366K297K
Total Non-current Assets140.62M86.65M3.99M207.16M61.62M
Total Assets437.19M561.12M484.18M621.82M448.37M
Account Payables3.17M2.66M2.49M1.68M841K
Short-term Debt0178K000
Tax Payables04.28M000
Deferred Revenue00000
Other Current Liabilities3.55M1.96M7.9M1.44M10.95M
Total Current Liabilities11.75M22.5M28.14M30.65M37.74M
Long-term Debt00001.9M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities65K0000
Total Non-current Liabilities65K3.59M2.15M849K1.9M
Total Liabilities11.81M26.09M30.29M31.5M39.64M
Common Stock4K5K4K6K6K
Retained Earnings(158.91M)(47.7M)(200.86M)(368.24M)(588.12M)
Accumulated OCI(838K)(2.6M)(129K)(133K)1.02M
Other Stockholders Equity00000
Minority Interest403K0192K00
Total Equity425.37M535.03M453.9M590.33M408.73M
Total Debt05.19M3.59M2.15M2.68M
Net Debt(59.77M)(150.96M)(94.84M)(80.85M)(85.65M)

Cullinan Therapeutics, Inc.

NASDAQ:CGEM

Intrinsic Alpha fair value

Locked

Current Price

$9.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.